APGE

Apogee Therapeutics, Inc. operates as a clinical-stage biotechnology company focused on developing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications. Headquartered in Thousand Oaks, California, the company was founded in 2022 and maintains a strategic partnership with its majority shareholder, Merck & Co., Inc. Apogee's pipeline includes APG777, a subcutaneous extended half-life antibody targeting interleukin-4 receptor alpha for atopic dermatitis, currently in Phase 2 clinical trials. The company also develops APG808, a subcutaneous extended half-life antibody that inhibits interleukin-13 for chronic obstructive pulmonary disease and asthma, and APG990, an antibody targeting OX40 ligand for atopic dermatitis and other inflammatory conditions. Apogee distinguishes itself through its proprietary antibody engineering platform designed to create therapies with extended dosing intervals, potentially improving patient convenience and compliance. The company completed its initial public offering in November 2023, raising approximately $252 million to advance its clinical programs. As of its most recent public filings, Apogee maintains a focused team of researchers and clinical development professionals dedicated to advancing its immunology-focused pipeline through clinical development and toward potential commercialization.